Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) Revenue
Annual & quarterly revenue history · segment & region breakdown
EDIT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsEditas Medicine, Inc. trailing twelve-month (TTM) revenue is $0.04B, an increase of 25.39% year-over-year from $0.04B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.04B | +$0.01B | +25.39% |
| 2024-12-31 | $0.03B | -$0.05B | -58.64% |
| 2023-12-31 | $0.08B | +$0.06B | +296.32% |
| 2022-12-31 | $0.02B | -$0.01B | -22.83% |
| 2021-12-31 | $0.03B | -$0.07B | -71.85% |
| 2020-12-31 | $0.09B | +$0.07B | +341.93% |
| 2019-12-31 | $0.02B | -$0.01B | -35.71% |
| 2018-12-31 | $0.03B | +$0.02B | +132.64% |
| 2017-12-31 | $0.01B | +$0.01B | +126.80% |
| 2016-12-31 | $0.01B | +$0.00B | +271.58% |
Compare revenue vs peers
BiotechnologyCompare EDIT revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Editas Medicine, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Editas Medicine, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Editas Medicine, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EDIT revenue · 4 questionsEDIT's trailing twelve-month (TTM) revenue is $0.04B. That is an increase of 25.39% year-over-year from $0.04B in FY2025.
▸ Source: FMP · Editas Medicine, Inc. SEC filings · GAAP · Editas Medicine, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026